Hepatitis b virus infection in homes for the aged
β Scribed by Maria Chiaramonte; Annarosa Floreani; Professor Remo Naccarato
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 466 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
A seroepidemiological study was carried out in three different institutions for the aged. Serological evidence of HBV infection and the HBsAg carrier rate were found to be significantly increased in all three institutions with respect to the control group (noninstitutionalized aged). Of the 24 HBsAg asymptomatic chronic carriers 62% were positive for HBeAg. Among 15 patients with acute viral hepatitis, none had a severe course and in three HBsAg was not cleared 4β18 months after transaminase levels became normal. During 12β18 months of followβup, two asymptomatic seroconversions to HBsAg were observed. Although no single HBV transmission route was identified, the close cohabitation with this high number of HBsAg/HBeAgβpositive asymptomatic subjects could lead to an increased risk of spread of HBV within such institutions. Failure to clear HBsAg and the mild, often subclinical, HBV infection observed in these subjects, may be due to immunological abnormalities present in the elderly.
π SIMILAR VOLUMES
In the present study we have investigated 53 patients with a spectrum of acute and chronic hepatitis B virus (HBV) infection for the presence of leucocyte HBV-DNA with the aid of molecular techniques. HBV-DNA was detected in peripheral blood mononuclear cells of 31 of 45 (69%) of chronic HBsAg carri
In a previous study a partial inhibition of viral replication was observed in HBeAg-positive patients after acyclovir (ACV) treatment. To assess those results and to evaluate different treatment regimens, a randomized controlled trial with ACV given at 45 mg/kg/day by continuous infusion (in 5 pati
to be controlled for in comparing immunoprophylactic approaches. At present, DNA polymerase activity or HBV DNA is useful for estimating the level of exposure. In an editorial in this issue, Dr. Dienstag pointed out difficulties in comparing the results of two immunoprophylactic regimens conducted a